Five steps to creating a research programme to support an effective pharma brand launch
During our 20+ years in business, we have supported the successful launch of over 1,000 global pharma brands across many therapy areas and territories.
This simple guide is aimed at helping companies who don’t have their own in-house research team. It outlines the key steps to creating a programme of research which will deliver the crucial insights for an effective marketing launch strategy.
Therapy Watch panel retention high during Covid-19
Our syndicated market tracking team has reported that, despite the COVID-19 pandemic, our panel retention rates remain high across all EU markets and Q1 reports have been delivered to all subscribers.
Is medical conference marketing now a long-distance relationship?
As more medical conferences plan to go virtual, John Branston reflects on the results of a study conducted among several hundred medical specialists about the future of these events and outlines how conference research is still possible in the age of COVID-19
As we all re-organise multiple aspects of our lives around new imperatives forced on us locally and globally by the coronavirus pandemic, it is worthwhile to think about how the short-term solutions we devise to achieve our objectives in the face of current limitations may have a long-lasting effects on familiar activities and behaviours.
Research Partnership publishes new patient Living with Anaemia in CKD EU & US reports
Living with Anaemia in CKD is a new syndicated report which offers valuable insights into patient attitudes and behaviour. The EU study was conducted amongst 105 patients and caregivers in France, Germany, Italy and Spain. The US study was conducted with 61 CKD patients and caregivers. For both studies the methodologies consisted of 30-minute quantitative online and 30-minute qualitative telephone interviews.
How we used online bulletin boards and an advisory board to help our client understand the dynamics of the payer environment
Our client had a product for the treatment and prophylaxis of bleeding in patients with Haemophilia A. Although the market had been stable, it was expected to change somewhat significantly as new products were due to be launched.
These new products would focus on the prophylaxis market and were expected to have better clinical and economic outcomes. There were opportunities and challenges for our client as the market was already competitive with many products already available. They needed to leverage the key value messages for their product to capitalise on the opportunities. As such, they needed to understand the dynamics of the payer environment and required competitor analysis to develop their communication strategy.